Edition:
United States

Bioporto A/S (BIOPOR.CO)

BIOPOR.CO on Copenhagen Stock Exchange

2.65DKK
21 Jul 2017
Change (% chg)

kr.-0.01 (-0.38%)
Prev Close
kr.2.66
Open
kr.2.66
Day's High
kr.2.73
Day's Low
kr.2.65
Volume
175,892
Avg. Vol
284,666
52-wk High
kr.2.95
52-wk Low
kr.1.40

Summary

Name Age Since Current Position

Thomas Magnussen

63 2013 Chairman of the Board

Peter Moerch Eriksen

56 2013 Chief Executive Officer

Torben Nielsen

56 2014 Vice Chairman of the Board

Jakob Christensen

2016 Chief Financial Officer

Jan Kuhlmann Andersen

55 2016 Chief Operation Officer

Finn Fjorder

2013 Executive Vice President Sales

Kirsten Drejer

61 2017 Director

Niels Nielsen

2016 Director

Christina Thomsen

Investor Relations Manager

Biographies

Name Description

Thomas Magnussen

Mr. Thomas Magnussen has served as Chairman of the Board of Directors of BioPorto A/S since April 16, 2013. He has been Member of the Company's Board since February 26, 2013. He holds a Master of Business Administration degree from INSEAD and a Master of Science degree and a Doctorate of Philosophy degree from Damarks Tekniske Universitet. He is Chairman of the Board of QuantumWise A/S and Zylinc A/S and Managing Director of Therazone ApS. He has experience in commercialization strategies and from industries including nanotechonolgy, ICT and medtech.

Peter Moerch Eriksen

Mr. Peter Moerch Eriksen has served as Chief Executive Officer (CEO) of BioPorto A/S since July 18, 2013. He has more than 15 years of experience within medtech/life science in Denmark and abroad. Previously, he was CEO of Sense A/S and prior to this, he held the position as VP of Medtronic in both the United States and Denmark. Mr. Moerch Eriksen has an accounting background supplemented with courses in management and is also Chairman of the Board of Ocumove ApS and Medtech Innovation Center. He also serves as Managing Director at PME Consult ApS and PME Holding ApS, as well as Member of Advisory Board at Lund University.

Torben Nielsen

Mr. Torben A. Nielsen has been Vice Chairman of the Board of Directors at BioPorto A/S since April 10, 2014. He has been Member of the Board of Directors of the Company since April 2, 2013. Torben A. Nielsen has over the past 25 years held senior positions in the financial sector - the last 10 years as member of the executive management in Sydbank responsible for asset management, capital markets, treasury, foreign and several other business areas as well as CEO of BankInvest. Concurrently, he has held several national and international board memberships, including NASDAQ OMX. Of a total of 30 years in the financial sector, of which 5 years in New York and London, Torben A. Nielsen built and managed businesses at home and abroad in all relevant commercial business areas in the financial sector and has been involved in and responsible for several mergers and acquisitions. He has DIEUs top management education, VL and banking education. He is Managing Director of Arnth Advice ApS and Member of the Board of Directors of Wavepiston A/S. He is also Partner of Linde & Partners Kapitalraadgivning A/S.

Jakob Christensen

Mr. Jakob Brix Christensen has been Chief Financial Officer at BIOPORTO A/S since January 1, 2016. Jakob has more than 10 years’ experience from financial management positions within medtech/life-science companies in Denmark and United States. Mr. Jakob Brix Christensen was previously member of the management team of Novozymes Biopharma (now Albumedix a/s) and before that Director of Investor Relations and US CFO at Origio. In addition to that Mr. Jakob Brix Christensen has been with GN Resound, Handelsbanken Capital Markets and Ernst&Young. Mr. Jakob Brix Christensen holds a Master of Science in Economics and Business administration from Aarhus Business School and a Graduate Diploma in Financial and Management Accounting (HD-R), supplemented by management training at Richmond University and Chicago Booth School of Business.

Jan Kuhlmann Andersen

Mr. Jan Kuhlmann Andersen has been appointed Chief Operation Officer of BIOPORTO A/S effective as of September 12, 2016. He no longer serves as Director of the Company effective as of September 12, 2016. He has held this position since April 10, 2015. Since 1995, Jan Kuhlmann Andersen has worked with sales within the life sciences area, mostly in United States-owned companies (FMC, Cambrex, Fisher Scientific and Thermo Fisher Scientific). Since 2007, Jan Kuhlmann Andersen has been Vice President, sales & marketing, in the Animal Health & Nutrition division in Chr. Hansen A/S. In addition, Jan Kuhlmann Andersen is the Chairman of the Board of Cytovac A /S. Until January 1, 2015, Jan Kuhlmann Andersen was also a Board member in Noscomed Medical Supply A / S and in the French Life Science company Cell Made. He holds Master of Science in Biology and Doctorate in Philosophy degrees.

Finn Fjorder

Mr. Finn Fjorder has been appointed Executive Vice President Sales at BioPorto A/S, effective as of October 1, 2013. He has 18 years of experience in the med-tech industry, most recently at Pnn Medical and before that at Medtronic. Mr. Fjorder holds a Master of Science degree in Chemistry from the Technical University of Denmark (Dammarks Tekniske Universitet), supplemented by management training from Copenhagen Business School.

Kirsten Drejer

Niels Nielsen

Christina Thomsen